Show simple item record

dc.contributor.authorYang, Justin C.
dc.contributor.authorRoman-Urrestarazu, Andres
dc.contributor.authorBrayne, Carol
dc.date.accessioned2020-03-04T04:15:24Z
dc.date.available2020-03-04T04:15:24Z
dc.date.issued2020-03-03
dc.date.submitted2019-03-20
dc.identifier.otherpone-d-19-08039
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/303007
dc.description.abstractObjective: To identify the geographic, organisational, and payment correlates of buprenorphine and methadone treatment among substance abuse treatment (SAT) providers. Methods: Secondary analyses of the National Survey of Substance Abuse Treatment Services (NSSATS) from 2007–16 were conducted. We provide bivariate descriptive statistics regarding substance abuse treatment services which offered buprenorphine and methadone treatment from 2007–16. Using multiple logistic regression, we regressed geographic, organisational, and payment correlates on buprenorphine and methadone treatment. Results: Buprenorphine is increasingly offered at SAT facilities though uptake remains comparatively low outside of the northeast. SAT facilities run by tribal governments or Indian Health Service which offer buprenorphine remain low compared to privately operated SAT facilities (AOR = 0.528). The odds of offering buprenorphine among facilities offering free or no charge treatment (AOR = 0.838) or a sliding fee scale (AOR = 0.464) was lower. SAT facilities accepting Medicaid payments showed higher odds of offering methadone treatment (AOR = 2.035). Conclusions: Greater attention towards the disparities in provision of opioid agonist therapies is warranted, especially towards the reasons why uptake has been moderate among civilian providers. Additionally, the care needs of Native Americans facing opioid-related use disorders bears further scrutiny.
dc.languageen
dc.publisherPublic Library of Science
dc.rightsAttribution 4.0 International (CC BY 4.0)en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en
dc.subjectResearch Article
dc.subjectMedicine and health sciences
dc.subjectSocial sciences
dc.subjectResearch and analysis methods
dc.titleResponses among substance abuse treatment providers to the opioid epidemic in the USA: Variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007-16
dc.typeArticle
dc.date.updated2020-03-04T04:15:24Z
prism.issueIdentifier3
prism.publicationNamePLOS ONE
prism.volume15
dc.identifier.doi10.17863/CAM.50083
dcterms.dateAccepted2020-02-14
rioxxterms.versionofrecord10.1371/journal.pone.0229787
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
datacite.contributor.supervisoreditor: Tsui, Judith I.
dc.contributor.orcidYang, Justin C. [0000-0003-2881-4906]
dc.identifier.eissn1932-6203


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's licence is described as Attribution 4.0 International (CC BY 4.0)